Comparative in vitro bactericidal activity between cefepime and ceftazidime, alone and associated with amikacin, against carbapenem-resistant Pseudomonas aeruginosa strains

Bantar, Carlos; Chiara, M. Di; Nicola, Federico; Relloso, Silvia; Smayevsky, Jorgelina

doi:10.1016/s0732-8893(99)00156-x

Cited by 12 publications

(10 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…No antagonism between cefepime and amikacin was observed [10]. Bantar et al [11] evaluated the bactericidal activity of cefepime and ceftazidime alone and associated with amikacin against some carbapenem-resistant P. aeruginosa strains. Cefepime (MIC, 16 Ìg/ml) combined with amikacin has shown the highest decrease in the viable cell count.…”

Section: Discussionmentioning

confidence: 99%

In vitro Activity of Combination Therapy with Cefepime, Piperacillin-Tazobactam, or Meropenem with Ciprofloxacin against Multidrug-Resistant <i>Pseudomonas aeruginosa</i> Strains

Erdem

Küçükercan²,

Ceran³

2003

Chemotherapy

View full text Add to dashboard Cite

The prevalence of multidrug-resistant Pseudomonas aeruginosa strains has been increasing every year, and treatment with various antimicrobial combinations has been offered alternatively in the clinical practice. The aim of this study was to evaluate the in vitro effects of combinations of meropenem, cefepime, or piperacillin-tazobactam with ciprofloxacin against multidrug-resistant P. aeruginosa strains by the time-kill method. The results show that both the combination of two beta lactams with ciprofloxacin and three beta lactams with ciprofloxacin against 4 of 5 multidrug-resistant P. aeruginosa strains has no effect in vitro. The combination of one beta lactam (meropenem, cefepime, piperacillin-tazobactam) with ciprofloxacin has a synergistic effect against one strain of multidrug-resistant P. aeruginosa that is ciprofloxacin susceptible and resistant to meropenem, cefepime, and piperacillin-tazobactam. None of the combinations had an antagonistic effect against these multidrug-resistant strains.

show abstract

Section: Discussionmentioning

confidence: 99%

In vitro Activity of Combination Therapy with Cefepime, Piperacillin-Tazobactam, or Meropenem with Ciprofloxacin against Multidrug-Resistant <i>Pseudomonas aeruginosa</i> Strains

Erdem

Küçükercan²,

Ceran³

2003

Chemotherapy

View full text Add to dashboard Cite

show abstract

“…The time-kill assays were carried out in duplicate as previously described [46] with some modifications. Briefly, cells were grown to log phase and sub-cultured into 10 mL CAMHB broth without (control) or with tigecycline (0.25 or 0.5 μg/mL) to a cell density of approximately 5 × 10 5 CFU/mL.…”

Section: Methodsmentioning

confidence: 99%

Role of the BaeSR two-component system in the regulation of Acinetobacter baumannii adeAB genes and its correlation with tigecycline susceptibility

Lin

Yeh

et al. 2014

BMC Microbiol

View full text Add to dashboard Cite

BackgroundTigecycline resistance in Acinetobacter baumannii is primarily acquired through overexpression of the AdeABC efflux pump. Besides AdeRS, other two-component regulatory systems (TCSs) involving the regulation of this transporter have not been clarified.ResultsIn this study, we found that the TCS genes baeR and baeS are co-transcribed and function as stress responders under high osmotic conditions. The baeSR and adeAB genes showed increased transcription in both the laboratory-induced and clinical tigecycline-resistant strains compared with the wild-type strain. The deletion of baeR in the ATCC 17978 strain led to 67–73% and 68% reduction in adeA and adeB expression, respectively, with a resultant 2-fold decrease in the tigecycline minimal inhibition concentration (MIC). In contrast, the overexpression of baeR resulted in a doubled tigecycline MIC, with a more than 2-fold increase in adeA and adeB expression. The influence of baeR knockout on adeAB gene expression can also be observed in the laboratory-induced tigecycline-resistant strain. A time-kill assay showed that the baeR deletion mutant showed an approximate 1-log10 reduction in colony forming units (CFUs) relative to the wild-type strain when the tigecycline concentration was 0.25 μg/mL throughout the assay period. The wild-type phenotype could be restored by trans-complementation with pWH1266-kan r -baeR. Increasing the tigecycline concentration to 0.5 μg/mL produced an even more marked 4.7-log10 reduction in CFUs of the baeR deletion mutant at 8 h, while only a 2.1-log10 reduction was observed for the wild-type strain.ConclusionsTaken together, these data show for the first time that the BaeSR TCS influences the tigecycline susceptibility of A. baumannii through the positive regulation of the resistance-nodulation-division efflux pump genes adeA and adeB.

show abstract

“…Third, the time‐kill analyses indicated that the cefepime plus amikacin combination seemed to be the most favourable of the tested options for treating infections caused by PDRPA. However, the in‐vitro data should be validated by assessing the clinical efficacy of various combinations of antimicrobial agents before specific recommendations can be made to modify existing treatment guidelines for infections caused by PDRPA [19]. In the present study, all PDRPA isolates had colistin MICs of ≤ 4 mg/L, which indicates that this agent may be an alternative choice for the treatment of PDRPA infections [20], although this agent is currently not available in Taiwanese hospitals.…”

Section: Clinical and Microbiological Characteristics Of 16 Patients mentioning

confidence: 99%

Pan-drug-resistant Pseudomonas aeruginosa causing nosocomial infection at a university hospital in Taiwan

Hsueh

Tseng

Teng

et al. 2005

Clinical Microbiology and Infection

View full text Add to dashboard Cite

This study evaluated the clinical and microbiological characteristics of 16 patients who were colonised or infected with 26 isolates of pan-drug-resistant Pseudomonas aeruginosa (PDRPA; intermediately-resistant or resistant to all cephalosporins, piperacillin-tazobactam, aztreonam, carbapenems, ciprofloxacin and aminoglycosides) in a university hospital during 1999-2002. All the isolates had colistin MICs < or = 4 mg/L, 19 (73%) isolates had bla(VIM-3), and 25 (96%) isolates had class I integrons (intI). Time-kill studies for two PDRPA blood isolates demonstrated synergism for cefepime-amikacin after 24 h. Pulsed-field gel electrophoresis analysis of the isolates revealed a polyclonal nature (12 pulsotypes), although clonal dissemination of PDRPA isolates among these patients was also present.

show abstract

Comparative in vitro bactericidal activity between cefepime and ceftazidime, alone and associated with amikacin, against carbapenem-resistant Pseudomonas aeruginosa strains

Cited by 12 publications

References 12 publications

In vitro Activity of Combination Therapy with Cefepime, Piperacillin-Tazobactam, or Meropenem with Ciprofloxacin against Multidrug-Resistant <i>Pseudomonas aeruginosa</i> Strains

In vitro Activity of Combination Therapy with Cefepime, Piperacillin-Tazobactam, or Meropenem with Ciprofloxacin against Multidrug-Resistant <i>Pseudomonas aeruginosa</i> Strains

Role of the BaeSR two-component system in the regulation of Acinetobacter baumannii adeAB genes and its correlation with tigecycline susceptibility

Pan-drug-resistant Pseudomonas aeruginosa causing nosocomial infection at a university hospital in Taiwan

Contact Info

Product

Resources

About